徐盛涛｜中国药科大学｜学者主页

2026

Development of High-Efficiency Mitochondrial Protease Targeting Chimeras (MtPTACs) for Targeted Degradation of POLRMT and Beyond

Cong Chen, Lihua Liu, Xinnan Li, Yuning Shi, Jieya Zhou, Lijuan Huang, Liyue Zeng, Dazhi Feng, Yunyue Wang, Xinyang Nie, Quanyi Huang, Yifei Wu, Shaokang Pang, Jinyi Xu, Shengtao Xu, Hong Yao

JACS Au

DOI

2026

Inside Back Cover: Structure‐Informed Design of Distinct Parallel G‐Quadruplex Stabilizers for KRAS ‐Driven Cancer Therapy (Angew. Chem. 32/2026)

Li Zhang, Kang Han, Xiaozhe Wang, Xiaolin Yu, Yongqiang Zhang, Sihan He, Zhiwei Han, Yushuang Liu, Jun‐Cheng Su, Jun Zhou, Shengen Yi, Shengtao Xu, Jinlei Bian, Kewei Zheng, Ling‐Yi Kong, K Y Wang

Angewandte Chemie

DOI

2026

Inside Back Cover: Structure‐Informed Design of Distinct Parallel G‐Quadruplex Stabilizers for KRAS ‐Driven Cancer Therapy (Angew. Chem. Int. Ed. 32/2026)

Angewandte Chemie International Edition

DOI

2026

ISGylation-mediated stabilization of CYP4Z1 fuels breast cancer initiation and progression

Yin Yuan, Y J Lu, Xuedan Han, Yidong Zhang, Qianqian Guo, Hong Yao, Qiyi Yu, Manzhen Zhou, Xinting Huang, Hongqi Wang, Miaomiao Niu, Jun Yin, Haibo Rong, Lei Huang, Xiaoman Li, Shengtao Xu, Lufeng Zheng

Experimental & Molecular Medicine

DOI

2026

Structure‐Informed Design of Distinct Parallel G‐Quadruplex Stabilizers for KRAS ‐Driven Cancer Therapy

Lulu Zhang, Kang Han, Xiaozhe Wang, Xiaolin Yu, Yongqiang Zhang, Sihan He, Zhiwei Han, Yushuang Liu, Jun‐Cheng Su, Jun Zhou, Shengen Yi, Shengtao Xu, Jinlei Bian, Kewei Zheng, Ling‐Yi Kong, K Y Wang

Angewandte Chemie

DOI

2026

In silico studies, synthesis, and biological evaluation of novel imidazopyridine-based CYP4Z1 inhibitors targeting breast cancer stem cells

Yu Lu, Kailin Chen, Hongqi Wang, Chi Zhang, Xinting Huang, Zihan Wang, Haitao Chen, Miaomiao Niu, Hong Yao, Lufeng Zheng, Shengtao Xu, Qianqian Guo

European Journal of Medicinal Chemistry

DOI

2026

Inside Front Cover: Oxidative Damage Fine‐Tunes G‐Quadruplex Structures in Human Gene Promoters (Angew. Chem. 21/2026)

Yu Wang, Yingying Wang, Rongshuang Cheng, Xinyuan Chen, Zhiyu Tang, Xing Wang, Yushuang Liu, Shuo‐Bin Chen, Shengtao Xu, Lingyi Kong, Kai‐Bo Wang

Angewandte Chemie

DOI

2026

Inside Front Cover: Oxidative Damage Fine‐Tunes G‐Quadruplex Structures in Human Gene Promoters (Angew. Chem. Int. Ed. 21/2026)

Yue Wang, Yue Wang, Rongshuang Cheng, Xinyuan Chen, Zhiyu Tang, Xing Wang, Yushuang Liu, Shuo‐Bin Chen, Shengtao Xu, Lingyi Kong, Kai‐Bo Wang

Angewandte Chemie International Edition

DOI

2026

Discovery of Novel HPK1 Inhibitors via Chemistry-Based Direct-to-Bioassay Screening and SAR Optimization

Yiping Duan, Chen He, Zhichao Guo, Kai Sun, Tiandong Zheng, Yang Lu, Baixue Zhang, Wenyi Zhong, Yansong Ren, Jie Liu, Shengtao Xu, Jinyi Xu

Journal of Medicinal Chemistry

DOI

2026

Oxidative Damage Fine‐Tunes G‐Quadruplex Structures in Human Gene Promoters

Yue Wang, Yue Wang, Rongshuang Cheng, Xinyuan Chen, Zhiyu Tang, Xing Wang, Yushuang Liu, Shuo‐Bin Chen, Shengtao Xu, Ling‐Yi Kong, Kai‐Bo Wang

Angewandte Chemie International Edition

DOI

2026

Discovery of a Novel Dual-Targeting KRAS G12D /HDAC Peptide Inhibitor for the Treatment of Pancreatic Cancer

Qiaoxuan Zhang, Yifei Geng, Haitao Chen, Jiaping Ni, Lixia Guan, Dongqing Zhai, Yuting Wang, Shengtao Xu, Miaomiao Niu, Lufeng Zheng, Weiwei Hu

Journal of Medicinal Chemistry

DOI

2026

Discovery of novel and potent 2-aminopyrazine-based HPK1 inhibitors enhancing T-cell immunity against cancer

Zhichao Guo, Yiping Duan, Baixue Zhang, Kai Sun, Tiandong Zheng, Lanlan Chen, Chen He, Jiajie Feng, Yang Lu, Geting Xiong, Shengtao Xu, Jie Liu, Zheying Zhu, Jinyi Xu

European Journal of Medicinal Chemistry

DOI

2026

Exploration of the mechanism of anlotinib in reversing PD-1 immunotherapy resistance: insights from single-cell sequencing

Wanjin Shi, Yidong Zhang, Qiyi Yu, Huilong Li, Miaomiao Niu, Shengtao Xu, Jun Yin, Xiaoman Li, Lufeng Zheng

Cancer Gene Therapy

DOI

2025

小分子疏水标签蛋白降解剂的研究进展

霍子瑞，裴捷雨，詹芳怡，谢绍文，徐进宜，徐盛涛

《中国药科大学学报》

2025

药学类新生研讨课教学思路探索与实践

徐盛涛，姚鸿，朱华健，罗姗姗，徐进宜

《药学教育》

DOI

2025

Bioorthogonal Chemistry: An Emerging Strategy for Targeted Protein Degradation

Pijun Zhou, Junda Li, Jinyi Xu, Yansong Ren, Shengtao Xu

Chemistry - A European Journal

DOI

2025

Discovery of Novel Bifunctional Agents as Potent TRK Inhibitors and Degraders against xDFG Mutation Resistance

Jian Zheng Song, Jingjie Zhu, Wenjian Zhu, Jinwei Feng, Jiarong Fan, Yi Mei, Qiren Shi, Yuzhuo Yang, Zhijie Feng, Peng George Wang, Tianduanyi Wang, Shengtao Xu, Jinyi Xu, Huajian Zhu

Journal of Medicinal Chemistry

DOI

2025

Construction of Small‐Molecule Deubiquitinase‐Targeting Chimeras to Reactivate and Stabilize Mutant p53 Y220C in Vitro and in Vivo

Chen He, Junda Li, Chenxi Cui, Jia Xie, Jiajie Feng, Baixue Zhang, Xingting Huang, Rui Ma, Lufeng Zheng, Jinyi Xu, Hong Yao, Shengtao Xu

Angewandte Chemie

DOI

2025

Development of Adamantane-based hydrophobic tags targeting anaplastic lymphoma kinase with enhanced antitumor activities

Jingjie Zhu, Fangyi Zhan, Jia Xie, Tonghao Fang, Yuan Sun, Feiyan Zhan, Tian Xiang Gao, J. Y. Liu, Jiajie Feng, Pijun Zhou, Huajian Zhu, Hong Yao, Zheying Zhu, Shengtao Xu, Jinyi Xu, Shengtao Xu

Bioorganic Chemistry

DOI

2025

Overcoming E3 Ligase-Mediated Resistance: Development of Novel Hydrophobic Tagging-Based Degraders Targeting ALK Protein

Shaowen Xie, Jingjie Zhu, Fangyi Zhan, Dazhi Feng, Chen He, Lihua Liu, Jia Xie, J. Y. Liu, Ming Zhong, Xingting Zhang, Jinyi Xu, Hong Yao, Shengtao Xu

Journal of Medicinal Chemistry

DOI

2025

The latest advances with natural products in drug discovery and opportunities for the future: a 2025 update

Shaowen Xie, Fangyi Zhan, Jingjie Zhu, Shengtao Xu, Jinyi Xu

Expert Opinion on Drug Discovery

DOI

2025

Selectively triggered: ROS-activated Michael acceptor prodrug strategy to enhance tumor targeting efficacy

Dazhi Feng, Xinnan Li, Junkai Liu, Xiao Shao, Lihua Liu, Yuning Shi, Yunyue Wang, Minghui Yu, Shuangtian Tang, Li Deng, Yongjie Zhang, Shaowen Xie, Jinyi Xu, Shengtao Xu, Hong Yao

Chemical Science

DOI

2024

In Vivo Self‐Assembly of PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy

Shaowen Xie, Jingjie Zhu, Yihan Peng, Fangyi Zhan, Feiyan Zhan, Chen He, Dazhi Feng, Jia Qing Xie, Jingyu Liu, Huajian Zhu, Hong Yao, Jinyi Xu, Zhigui Su, Shengtao Xu

Angewandte Chemie

DOI

2024

An updated review of small-molecule HPK1 kinase inhibitors (2016-present)

Yiping Duan, Zhichao Guo, Wenyi Zhong, Jichao Chen, Shengtao Xu, Jie Liu, Jinyi Xu

Future Medicinal Chemistry

DOI

2024

Palladium-Mediated Bioorthogonal System for Prodrug Activation of N-Benzylbenzamide-Containing Tubulin Polymerization Inhibitors for the Treatment of Solid Tumors

Jinlong Li, Tong Zhang, Di Wu, Chen He, Haoxiang Weng, Tiandong Zheng, Jie Liu, Hong Yao, Jichao Chen, Yansong Ren, Zheying Zhu, Jinyi Xu, Shengtao Xu

Journal of Medicinal Chemistry

DOI

2024

Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules

Zhichao Guo, Yiping Duan, Kai Sun, Tiandong Zheng, Jie Liu, Shengtao Xu, Jinyi Xu

European Journal of Medicinal Chemistry

DOI

2024

Hit-to-Lead Optimization of the Natural Product Oridonin as Novel NLRP3 Inflammasome Inhibitors with Potent Anti-Inflammation Activity

Chen He, Junkai Liu, Junda Li, Hongyu Wu, Chenyang Jiao, Xiaotong Ze, Shengtao Xu, Zheying Zhu, Wenjie Guo, Jinyi Xu, Hong Yao

Journal of Medicinal Chemistry

DOI

2023

Current development of bicyclic peptides

Dazhi Feng, Lihua Liu, Yuqi Shi, Pian Du, Shengtao Xu, Zheying Zhu, Jinyi Xu, Hong Yao

Chinese Chemical Letters

2023

Recent advances of vacuolar protein-sorting 34 inhibitors targeting autophagy

Long Chen, Tian Gao, Pijun Zhou, Wenxuan Xia, Hong Yao, Shengtao Xu, Jinyi Xu

Bioorganic Chemistry

DOI

2023

Design, synthesis and biological evaluation of novel dihydroquinolin-4(1H)-one derivatives as novel tubulin polymerization inhibitors

Yuchen Tan, Han Hu, Wenjian Zhu, Wenjian Zhu, Tao Wang, Tian Xiang Gao, Hongqi Wang, Jian Chen, Shengtao Xu, Jinyi Xu, Shengtao Xu, Huajian Zhu

European Journal of Medicinal Chemistry

DOI

2023

Small-Molecule Hydrophobic Tagging: A Promising Strategy of Druglike Technology for Targeted Protein Degradation

Shaowen Xie, Jingjie Zhu, Junda Li, Feiyan Zhan, Hong Yao, Jinyi Xu, Shengtao Xu

Journal of Medicinal Chemistry

DOI

2023

Advances of bioorthogonal coupling reactions in drug development

Feiyan Zhan, Jingjie Zhu, Shaowen Xie, Jinyi Xu, Shengtao Xu

European Journal of Medicinal Chemistry

DOI

2023

Design, Synthesis, and Biological Evaluation of Novel Hybrids Containing Dihydrochalcone as Tyrosinase Inhibitors to Treat Skin Hyperpigmentation

Songtao Xue, Zhiwei Li, Xiaotong Ze, Xiuyuan Wu, Chen He, Shuai Wen, Maria Marlow, Jian Chen, David J. Scurr, Zheying Zhu, Jinyi Xu, Shengtao Xu

Journal of Medicinal Chemistry

DOI

2023

Discovery of Norbornene as a Novel Hydrophobic Tag Applied in Protein Degradation

Shaowen Xie, Feiyan Zhan, Jingjie Zhu, Yuan Sun, Huajian Zhu, Jie Liu, Jian Chen, Zheying Zhu, Dong‐Hua Yang, Zhe‐Sheng Chen, Hong Yao, Jinyi Xu, Shengtao Xu

Angewandte Chemie

DOI

2022

Molecular glues modulate protein functions by inducing protein aggregation:A promising therapeutic strategy of small molecules for disease treatment

Hongyu Wu, Hong Yao, Chen He, Yilin Jia, Zheying Zhu, Shengtao Xu, Dahong Li, Jinyi Xu

Acta Pharmaceutica Sinica B

2020

Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer

Hong Yao, Shaowen Xie, Xiaoqian Ma, Junkai Liu, Hongyu Wu, Aijun Lin, Hequan Yao, Dahong Li, Shengtao Xu, Dong‐Hua Yang, Zhe‐Sheng Chen, Jinyi Xu

Journal of Medicinal Chemistry

DOI

2019

Controllable thioester-based hydrogen sulfide slow-releasing donors as cardioprotective agents

Hong Yao, Shanshan Luo, Junkai Liu, Shaowen Xie, Yanpeng Liu, Jinyi Xu, Zheying Zhu, Shengtao Xu

Chemical Communications

DOI

2017

冬凌草甲素抗肿瘤作用机制及其结构改造研究进展

胡梅，徐盛涛，徐进宜

《药学与临床研究》

2017

五环三萜羽扇豆烷型天然产物抗肿瘤活性研究进展

王艺玮，徐盛涛，徐进宜

《药学与临床研究》

2017

吴茱萸碱类衍生物的生物活性研究进展

裘杨溢，徐盛涛，徐进宜

《药学与临床研究》

2017

Design, synthesis, biological evaluation, and docking study of 4‐isochromanone hybrids bearing N‐benzyl pyridinium moiety as dual binding site acetylcholinesterase inhibitors (part II )

Jia Wang, Chaolei Wang, Zheng Qiu Wu, Xinnan Li, Shengtao Xu, Jie Liu, Qinying Lan, Zheying Zhu, Jinyi Xu

Chemical Biology & Drug Design

DOI

2013

天然活性产物异色满-4-酮肟醚类衍生物的合成及其β-肾上腺素受体阻断活性(英文)

白仁仁，徐盛涛，刘洁，洪文，汤依群，吴晓明，谢唯佳，姚和权，徐进宜

Chinese Journal of Natural Medicines

2012

ChemInform Abstract: The Conversion of Oridonin to Spirolactone‐Type or Enmein‐Type Diterpenoid: Synthesis and Biological Evaluation of ent‐6,7‐seco‐Oridonin Derivatives as Novel Potential Anticancer Agents.

Lei Wang, Dahong Li, Shengtao Xu, Hao Cai, Hequan Yao, Yihua Zhang, Jieyun Jiang, Jinyi Xu

ChemInform

DOI

精选作品

期刊论文

Development of High-Efficiency Mitochondrial Protease Targeting Chimeras (MtPTACs) for Targeted Degradation of POLRMT and Beyond

Inside Back Cover: Structure‐Informed Design of Distinct Parallel G‐Quadruplex Stabilizers for KRAS ‐Driven Cancer Therapy (Angew. Chem. 32/2026)

Inside Back Cover: Structure‐Informed Design of Distinct Parallel G‐Quadruplex Stabilizers for KRAS ‐Driven Cancer Therapy (Angew. Chem. Int. Ed. 32/2026)

ISGylation-mediated stabilization of CYP4Z1 fuels breast cancer initiation and progression

Structure‐Informed Design of Distinct Parallel G‐Quadruplex Stabilizers for KRAS ‐Driven Cancer Therapy

In silico studies, synthesis, and biological evaluation of novel imidazopyridine-based CYP4Z1 inhibitors targeting breast cancer stem cells

Inside Front Cover: Oxidative Damage Fine‐Tunes G‐Quadruplex Structures in Human Gene Promoters (Angew. Chem. 21/2026)

Inside Front Cover: Oxidative Damage Fine‐Tunes G‐Quadruplex Structures in Human Gene Promoters (Angew. Chem. Int. Ed. 21/2026)

Discovery of Novel HPK1 Inhibitors via Chemistry-Based Direct-to-Bioassay Screening and SAR Optimization

Oxidative Damage Fine‐Tunes G‐Quadruplex Structures in Human Gene Promoters

Discovery of a Novel Dual-Targeting KRAS G12D /HDAC Peptide Inhibitor for the Treatment of Pancreatic Cancer

Discovery of novel and potent 2-aminopyrazine-based HPK1 inhibitors enhancing T-cell immunity against cancer

Exploration of the mechanism of anlotinib in reversing PD-1 immunotherapy resistance: insights from single-cell sequencing

小分子疏水标签蛋白降解剂的研究进展

药学类新生研讨课教学思路探索与实践

Bioorthogonal Chemistry: An Emerging Strategy for Targeted Protein Degradation

Discovery of Novel Bifunctional Agents as Potent TRK Inhibitors and Degraders against xDFG Mutation Resistance

Construction of Small‐Molecule Deubiquitinase‐Targeting Chimeras to Reactivate and Stabilize Mutant p53 Y220C in Vitro and in Vivo

Development of Adamantane-based hydrophobic tags targeting anaplastic lymphoma kinase with enhanced antitumor activities

Overcoming E3 Ligase-Mediated Resistance: Development of Novel Hydrophobic Tagging-Based Degraders Targeting ALK Protein

The latest advances with natural products in drug discovery and opportunities for the future: a 2025 update

Selectively triggered: ROS-activated Michael acceptor prodrug strategy to enhance tumor targeting efficacy

In Vivo Self‐Assembly of PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy

An updated review of small-molecule HPK1 kinase inhibitors (2016-present)

Palladium-Mediated Bioorthogonal System for Prodrug Activation of N-Benzylbenzamide-Containing Tubulin Polymerization Inhibitors for the Treatment of Solid Tumors

Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules

Hit-to-Lead Optimization of the Natural Product Oridonin as Novel NLRP3 Inflammasome Inhibitors with Potent Anti-Inflammation Activity

Current development of bicyclic peptides

Recent advances of vacuolar protein-sorting 34 inhibitors targeting autophagy

Design, synthesis and biological evaluation of novel dihydroquinolin-4(1H)-one derivatives as novel tubulin polymerization inhibitors

Small-Molecule Hydrophobic Tagging: A Promising Strategy of Druglike Technology for Targeted Protein Degradation

Advances of bioorthogonal coupling reactions in drug development

Design, Synthesis, and Biological Evaluation of Novel Hybrids Containing Dihydrochalcone as Tyrosinase Inhibitors to Treat Skin Hyperpigmentation

Discovery of Norbornene as a Novel Hydrophobic Tag Applied in Protein Degradation

Molecular glues modulate protein functions by inducing protein aggregation:A promising therapeutic strategy of small molecules for disease treatment

Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer

Controllable thioester-based hydrogen sulfide slow-releasing donors as cardioprotective agents

冬凌草甲素抗肿瘤作用机制及其结构改造研究进展

五环三萜羽扇豆烷型天然产物抗肿瘤活性研究进展

吴茱萸碱类衍生物的生物活性研究进展

Design, synthesis, biological evaluation, and docking study of 4‐isochromanone hybrids bearing N‐benzyl pyridinium moiety as dual binding site acetylcholinesterase inhibitors (part II )

天然活性产物异色满-4-酮肟醚类衍生物的合成及其β-肾上腺素受体阻断活性(英文)

ChemInform Abstract: The Conversion of Oridonin to Spirolactone‐Type or Enmein‐Type Diterpenoid: Synthesis and Biological Evaluation of ent‐6,7‐seco‐Oridonin Derivatives as Novel Potential Anticancer Agents.

会议论文

Construction of some libraries of novel diterpenoid analogues:design,synthesis and biological evaluation